This paper summarises the views of the authors on the provision of a prolactin assay service. We discuss the pathophysiology of prolactin secretion and the clinical indications that arise from that. We cover the rather complex issue of the definition of normal and elevated prolactin levels. From these considerations, certain guidelines on the analytical performance of prolactin assays and their provision in a clinical biochemistry service are given. The extent to which currently available methods and performance as revealed by the UK External Quality Assessment Scheme (EQAS) match these guidelines are described and certain conclusions are reached. Finally, probable future developments are briefly discussed.
(i) Reagents of appropriate quality are available to enable prolactin immunoassays to be provided in UK clinical biochemistry laboratories. These are provided either separately or in the form of kits from both commercial and NHS sources. There is no requirement for individual laboratories to undertake their own antiserum production or prolactin iodination. (ii) Acceptable performance (as defined using internal QC procedures and the UK EQAS) is achievable using these reagents/kits, although one commercial kit shows a consistent marked negative bias. (iii) Reference ranges, including 'normal ranges', show considerable betweencentre variability. Many centres have not established their own ranges, even those using in-house methods. Reference ranges for use in clinical biochemistry laboratories are proposed in this report. (iv) Some general guidance on the provision of a prolactin service is given, although this does not differ in principle from that appropriate for other peptide hormone analytes. There is no evidence that centres with small workloads perform any worse than average, although it may be more costefficient for such centres to send the samples elsewhere. (v) As with other peptide analytes, non-isotopic immunometric methodology is likely to replace current radioimmunoassay methods in the llf;,ar future. 
Chemistry
Human pituitary prolactin is a single-chain polypeptide of 198 amino acid residues (M r 22554). It has been fully sequenced and has structural homologies with human growth hormone and human placental lactogen. The source of the prolactin present in high concentration in human amniotic fluid is the decidua; this prolactin appears to be of identical structure to pituitary prolactin and has been used as the basis of immunoassay reagents. Fractionation (by gel filtration, for example) of immunoreactive-prolactin has revealed heterogeneity both in pituitary extracts and in some, but not all, samples of peripheral blood (see Fig. 2 ). Two larger forms are identified: 'big' prolactin, which is probably a dimer and 'big-big' prolactin which is presumably an aggregated form. There is some dispute regarding the analytical and biological significance of these different forms.
Secretion
Prolactin is secreted from acidophilic 'lactotroph' cells in the adenohypophysis (anterior pituitary). These cells are few in number in the human pituitary except during pregnancy and lactation when the anterior pituitary increases in size several-fold due to the increase in these cells. Several factors are involved in the regulation of prolactin secretion.
Regulation by hypothalamic factors. In the human, prolactin secretion is under predominant inhibitory control by a hypothalamic prolactin inhibiting factor (PIF) which is the catecholamine, dopamine. Whether there is a separate prolactin-releasing factor (PRF) is not clearly established in the human. Thyrotrophin releasing hormone (TRH) administered intravenously at the dose required to produce an increase in TSH secretion, also produces a release of prolactin.
Time-related changes. Prolactin secretion varies on a time-scale ranging from minutes to decades. The most important of these for the clinical biochemist is the sleep-related nocturnal increase in secretion seen in normal individuals. Prolactin levels in blood are 2-3 times higher during the night than in the afternoon. Even at 8 or 9 a.m. the levels are 2G-30% higher than at midday. On the other hand, short-term 'pulses' occur but are less regular than, for example, those of the gonadotrophins.
Assays for prolactin 639
The biological half-life of prolactin is about 20 min. Changes during the menstrual cycle are not marked: there may be a slight mid-cycle elevation, possibly oestrogen-induced. On a longer time scale, an extensive study involving women from Japan and USA 3 revealed a circannual rhythm of prolactin secretion, with the nocturnal increase being more marked in autumn and winter, particularly in the Japanese women. Pregnancy and lactation. Prolactin secretion increases throughout pregnancy until term. Suckling is an important physiological stimulus to prolactin release and in the post-partum period prolactin concentrations are correlated with the frequency of suckling.
Oestrogens. Oestrogens have a direct action on the pituitary to increase prolactin secretion. This effect is dose-dependent: currently used low-dose (2G-30 Ilg ethinyl oestradiol) combined oral contraceptives do not elevate prolactin levels."
Drugs. Drugs which deplete hypothalamic dopamine or block its action, such as the phenothiazines, increase prolactin secretion.f A drug history is an important feature of the investigation of raised prolactin levels.
Stress. Major stress (e.g. general anaesthesia, abdominal surgery) undoubtedly raises prolactin levels several-fold. The frequently stated view that minor stress (e.g. psychological, outpatient attendance, venepuncture) raises prolactin levels, is controversial and lacks objective evidence. One very short papers is frequently cited, although others have shown no effect of out-patient attendance or venepuncture." One of us has proposed that the tail-end of the nocturnal increase is a cause of an apparent venepuncture-associated increase which is not real. 7
Functions of prolactin
Apart from its role in breast development and milk production during pregnancy and lactation, prolactin has no known role either in men or non-pregnant women.
CLINICAL USES OF PROLACTIN ASSAYS

Definition of normal prolactin levels
The use of the phrase 'elevated prolactin levels' and the term 'hyperprolactinaernia' implies that there is a range of prolactin levels which can be defined as normal. The laboratory worker usually defines the normal range by measuring the values in a number of presumed healthy subjects, the range then being obtained by trimming off any extreme values using parametric statistics or percentiles.
There are three practical problems in defining 'normal' prolactin values." These relate to the population studied, the statistical processing of the data, and the analytical method used. Unselected normal subjects may be too ill-defined to serve as a reference group for determination of a normal range, bearing in mind the effects of medication and physiological changes in prolactin levels. A second problem can arise when inappropriate statistics are used to define the range.
There is considerable evidence that prolactin values in the normal population do not form a gaussian distribution but are skewed and more accurately fitted to a logarithmic scale. Neglect of this by use of gaussian statistics on untransformed data leads to upper limits of normal as low as 290 mUlL being used," resulting in a marked overuse of the term 'hyperprolactinaemia'. The wide range of upper limits of normal used by laboratories in the UK is illustrated in Fig. 1 and indicates a major, non-analytical, cause of between-centre discrepancy in the interpretation of prolactin results.
Finally, difficulties may be caused when values obtained in individual subjects are compared with values in normal subjects measured in a different laboratory, using a different assay technique, or indeed in the same laboratory when methodological improvements or changes have been introduced. These methodological problems are probably less than they were previously? and will be discussed below.
In short, normal levels of prolactin may be hard to define both conceptually and practically and this is reflected in differences between centres in the reported incidence of apparent hyperprolactinaemia and the way in which it is diagnosed and treated.
Hyperprolactinaemia
Definition. In essence. the term 'hyperprolactinaernia' is a biochemical description and not a clinical state. The use of a normal range, however defined, means that any prolactin value above the upper limit of normal is 'elevated' and represents hyperprolactinaemia. If allowance is not made for the non-gaussian distribution of values this may be as high as 5-8% of women attending outpatient clinics." Over-diagnosis because of misinterpretation of normal ranges is not uncommon in medicine and hyperprolactinaemia appears to be a good example of an upper limit syndrome. III The situation is not clarified by the essentially arbitrary use of 'twice the upper limit of normal' as a decision point. II Sub-types of the term hyperprolactinaemia are even used as clinicians struggle to fit biochemical findings into their preconceptions. Thus, 'mild', 'moderate', 'functional', 'transient' and 'latent' are all qualifying adjectives that are applied to hyperprolactinaemia. These attempts are misguided and hinder progress in the evaluation of prolactin results. What now seems to be required is that the term hyperprolactiaaernia should be used more rigorously and further evaluations of the clinical significance and predictive value of particular prolactin levels should be carried out. Reference ranges based on such evaluations are discussed below (and shown in Table 2 ). Causes of hyperprolactinaemia. There are numerous causes of hyperprolactinaemia which are listed in Table 1 . Most of these causes may be revealed by a detailed clinical history supported by other biochemical tests (e.g. of renal or thyroid function). Having excluded these, the diagnosis rests between a prolactinsecreting tumour of the pituitary (either a micro-or a macro-prolactinoma) and 'hypothalamic hyperprolactinaemia'.
Reference ranges in pathological states (female subjects)
Although figures in the region of 35G--400 mUlL are frequently quoted and widely used as an 'upper limit of normal' distinguishing normoprolactinaemia from hyperprolactinaemia, it is clear that they are based upon a number of false assumptions.": 'I Extensive clinical experi-ence 2 . 12-14 suggests that the reference ranges shown in Table 2 are appropriate.
Reference ranges in male subjects
Prolactin concentrations in the serum of normal men are somewhat lower than those of women (the median value is about 10% lower). There is less information than in the female subject upon which to establish reliable reference ranges but values above 1000 mUlL should be considered pathological, and as in women, once factors such as drugs and renal failure have been excluded, a prolactinoma should be suspected. The higher the prolactin value, the more likely the diagnosis of macroprolactinoma.
Role of prolactin assays in diagnosis and monitoring therapy
Single sample (female) subjects. If the result is less than 700 mUlL, pathology is virtually excluded and it is reasonable not to assay a repeat specimen. Some centres, however, re- 
2IXX}-4IXXI 4IXl(}-6(XXl Above 6lXXl~N ormal (though an occasional prolactinoma may present in the 4SD-700 range) Doubtful pathological significance (consider assay of a repeat sample) Microprolactinoma; drugs; polycystic ovarian disease; hypothalamic disorder including 'functionless' pituitary tumour with suprasellar extension); primary hypothyroidism Microprolactinoma; hypothalamic disorder; drugs (less likely) Prolactinoma (almost certainly); hypothalamic disorder (possibly) Macroprolactinoma (almost certainly) peat the assay if the prolactin level is above 400-500 mUlL, if clinical circumstances indicate. That too is reasonable. If above 700 mUlL, and non-pathological factors such as pregnancy and drug therapy have been excluded, the assay should be repeated once or, if thought necessary, twice. The higher the value the more certain the diagnosis and the less the need for a repeat specimen. If raised, a biochemical diagnosis of hyperprolactinaemia is made (note that this is not a clinical or pathological entity but a biochemical description). The level of prolactin will aid in the differential diagnosis (see Table 2 ).
Monitoring (female) subjects. The assay of prolactin in serum is undoubtedly one of the most useful assays for tumour-related antigens and is of crucial value in the long-term management of prolactinomas.
(i) Untreated prolactinomas. Prolactinomas, particularly small ones, have a natural history of slow growth and may show no progression over 5-10 years. Unless there is a clinical indication, such tumours do not necessarily require treatment and prolactin measurements can be used for long-term assessment. (ii) Pregnancy in women with hyperprolactinaemia. Prolactin measurements are not particularly helpful in this situation since prolactin concentrations increase to 5000--{jOOO mUlL during normal pregnancy and the actual level is difficult to interpret. Elevation of concentrations beyond those associated with normal pregnancy, together with clinical symptoms, is seen by some centres as an indication for therapy. (iii) To test efficacy of treatment (medical, surgical, radiotherapy, or combinations). Since the serum prolactin concentration is directly related to the size of a prolactinoma, its measurement is widely applied to assess the effectiveness of therapy. Once the level is in the normal range, it is not necessary to repeat at each out-patient visit unless such a repeat is indicated on clinical grounds (e.g. change in symptoms). (iv) To check compliance. Prolactin-lowering dopamine agonists frequently produce side-effects which may be minor or may be intolerable for some patients. Compliance can therefore be checked by prolactin measurement.
In the male subjects (i) Prolactinomas. Men with prolactinomas usually have a large tumour; the commonest presenting symptoms are loss of libido and impotence or visual field defects. Prolactin assays are of value in the management of such patients, as in women. (ii) Infertility. There is no evidence that raised prolactin levels are found in infertile men and prolactin assays should play no part in the routine investigation of such patients unless a prolactinoma is suspected for other reasons.
Dynamicfunction tests. The principle of these tests is that a prolactinoma may be autonomous and so subject to altered dopaminergic control. Many tests have been investigated, but the most useful are those based on an anti-dopaminergic agent, such as metoclopramide or domperidone. Patients with a proven prolactinoma have diminished « 150% relative to basal) serum prolactin response to these agents, compared with either normal controls or women presumed to have non-tumourous hyperprolactinaemia. The serum TSH response to the same anti-dopaminergic drug is greater in the patient with a prolactinoma than in either of the control groups. However, the overlap between patient groups is such that a firm diagnosis cannot always be made in the individual case. In general, dynamic function tests provide little additional information to measurement of basal levels. They are found to be useful in centres in which surgery is first line therapy for a microprolactinoma with a normal pituitary fossa. 15 . Ih
PERFORMANCE CRITERIA
In general, there is no particular clinical requirement for highly precise and reproducible assays for prolactin as the values are distributed over a wide scale. However, in the interest of good laboratory practice, prolactin assays should be as precise and reproducible as possible, as well as being unbiased, rapid, simple and cheap.
Within-batch precision
The mid-point of the working range as assessed by the precision profile!" should be in the region 500-1000 mUlL, although assays are frequently targetted below this because the majority of samples encountered clinically have values in the 100-400 mUlL region. Since there is no evidence to suggest that hypoprolacti-naemia is clinically relevant and, since levels in the region 2000 mUlL and above are clinically important, it would seem preferable to target assays in the region 50D-1000 mUlL, which is a diagnostic grey area. Internal and External QC samples should be selected on the same basis. A within-batch imprecision of 10% CV or better is achievable over the working range of the assay.
Between-batch reproducibility
Using suitable internal quality control (QC) pools, between-batch reproducibility should not be greater than 15% CV and preferably less than 10%. The general principles are no different from those operating in other hormone assays'? and will not be discussed at length.
Bias
Assessing the analytical validity of a prolactin Assays for prolactin 643 assay is the same in principle as for other polypeptide hormones.
Parallelism. Parallelism of unknown with standard reference materials is readily tested, although the significance of deviation from parallelism at high doses is not clear.
Chromatographic fractionation. The presence of macromolecular forms can be demonstrated in some samples by chromatographic fractionation and comparison with reference material containing monomeric protein (Fig. 2) .
Bioassays. Bioassays for prolactin are not widely available. Even the most practicable in vitro assay (the rat lymphoma cell culture assay for lactogenic hormones) is beyond the expertise of most clinical biochemistry laboratories.
Clinical and pharmacological validation. This is an approach that could be adopted by any laboratory. The assay should show appropriate responses in prolactin level to well-defined stimuli such as insulin-induced hypo glycaemia or thyrotrophin releasing hormone (TRH) and suppression to undetectable levels with dopamine agonist drugs such as bromocriptine.
Comparison with other immunoassay methods. This is a frequent practice in the evaluation of a new method. It does not give objective evidence of accuracy (lack of bias). Comparison can be carried out in-house and! or through an External Quality Assessment Scheme.
Recovery experiments. Known amounts of the designated reference preparation are added to pools of biological fluid and the recovery measured. It is important to realise that quantitative recovery does not prove analytical validity.
Practical performance criteria
Although many conventional methods use relatively short incubation times and analyses are completed within one working day, there is normally no clinical requirement for such rapidity and overnight incubation is often more labour-efficient. A turn-around time of 2-3 weeks would seem reasonable, and if the sample throughput is below the numbers that can be processed efficiently in that time period (say 15 per week) then a laboratory should question whether it would not be better to have prolactin analyses done elsewhere. There are, however, situations in which speed could be important, e.g. in the management of a prolactinoma in a patient reporting acute visual field changes. Furthermore, multiple requesting and reporting (e.g. thyroxine or cortisol on the same sample) is more efficient if all the analyses have a similar turn-around time.
Review of available methods
PROLACTIN KITS
Information derived from a survey, carried out in early 1985 of the 131 participants in the UK EQAS, and from which there was an 88% response, has been used to draw up the following sections.
Prolactin kit usage in UK
The prolactin assay field in the UK is heavily kit-dominated, reflecting the widespread uptake of the assay in centres with a clinical demand but without special facilities, e.g. for labelling antigen. Table 3 shows the kits in use in the UK and the percentage of laboratories using each kit. Technical details of the commercially available kits for prolactin are available from manufacturers and in tabular form from S.L.l. It was apparent from the responses that some users modify the kits, most often to the use of half volumes of reagents as an economy measure. There is no evidence that such modifications adversely affect performance (assessed internally or through the UK EQAS), but care must always be taken when validated protocols are altered.
Special aspects of prolactin assays in UK
Working ranges. Almost all laboratories take the working range of their assays on undiluted samples to equal the range of their standards, i.e. if the least concentrated standard is 48 mUlL and the most concentrated standard is 6500 mUlL, such a laboratory defines its working range as 48-6500 mUlL, irrespective of whether a precision profile is constructed. It is possible, but unlikely, that a laboratory exhibits excellent precision over the whole of that range. Ten per cent of responding laboratories claim that their working ranges start at zero prolactin.
Precision profiles. Two thirds (64%) of responders claimed to have constructed a precision profile at some time or other, while 27% construct one on each run. Of these, roughly one third had written their own software, while the rest use conventional packages which calculate the profiles. Details of how the profiles were constructed were not sought.
QC Pools. A majority (80%) of laboratories include three or more QC pools, while 11% include only two. Only three participants re-ported having a OC pool with a value of greater than 2800 mUlL, yet 68% reported that their working ranges exceeded that figure. A further 15% reported that upper limit of their working range was 2000 mUlL, but 50% of these did not have OC pools above 1500 mUlL.
Data processing. A few laboratories (7% of responders) fit their data manually (one using a 4 parameter, non-linear fit!) and 16% have written their own software for a variety of microcomputers (chiefly Apple). Most (60%) use software provided by the manufacturer of the counting apparatus which offer a variety of curve fitting techniques from 4-parameter log! logit to spline functions. There are insufficient data from prolactin assays to draw conclusions regarding the most appropriate curve fitting and dose-interpolation procedures.
Calibration standards and units. Except for those using kits directly calibrated against 75/504 (the current international reference preparations, IRP), all kit users convert their standard values to mUlL of 75/504 using conversion factors supplied by the kit manufacturers. In the 'own method' group, two 'use preparation 81/541 (an interim material not of IRP status) calibrated against 75/504, seven obtain standards from commercial sources (including NETRIA and Chelsea) and two have calibrated hyperprolactinaemic serum against 75/504. A majority of laboratories report their patient results (correctly) in milliunits per litre, but 6% report results in microunits per millilitre, 2% in nanograms per millilitre and I'Yo in micrograms per litre.
Dilution of high samples. 45% of laboratories claimed not to assay high concentration samples at a dilution. This is not surprising in view of the working ranges claimed for many assays, but is a matter of concern in view of the need for an effective monitoring of therapy. Of those laboratories which do dilute high samples, a few analyse all samples both neat and diluted; 10% of centres have observed non-parallelism in a few samples.
Workload. The total UK annual workload estimated from the responses is 213 000 samples, which, correcting for the 88% return rates, gives an approximate workload of260 000 samples. The devolution of this assay from the Supraregional Assay Service (SAS) has caused a rapid uptake of the assay by small laboratories and 71% of laboratories are analysing less than 40 samples per week. The majority of laboratories run one assay a week, but 38% of UK centres are running one assay per fortnight, with 3% even less frequently than that. This frequency could have implications for quality control and the reliability of reference range data, although it must be said that there is no objective evidence for this in the case of prolactin assays.
Reference ranges. Over half (56%) of UK centres had not established their own reference ranges and most relied on data supplied by kit manufacturers. The remainder used such unreliable sources as 'literature values', 'local values' or 'values obtained from a Centre of Excellence' (whatever that may be). Not surprisingly, therefore, there was some (though divergent and insecurely based) agreement about the 'normal' levels of prolactin with clusters around 360, 400, 500 and 700 mUlL (Fig. 1) .
Only a minority of 'in-house' assay users have determined their own reference ranges. Of those, about half have different ranges for men and women, the upper limits of normal ranging from 150 to 585 mUlL for men and from 300 to 680 mUlL for women. In the compiling of this information, the poor response to the questionnaire by own-method users was disappointing.
Reagents for in-house assays. Antisera were obtained from Guildhay (43% of responders) and St Bartholomew's Hospital (14%). The rest used antisera from a variety of sources. Only 29% produce their own labelled antigen, virtually all of the rest obtaining it from NETRIA.
Clinical uses of the assay. All laboratories stated that the investigation of gonadal dysfunction in women was the major use for their assay, with the investigation of infertility in men and the management of hyperprolactinaemic patients coming joint second. Few laboratories reported that other uses accounted for more than 5% of their total workload and those laboratories which specified the other uses quoted epilepsy investigations, pituitary function tests and the investigation of 'oversuppression' by bromocriptine as the main uses.
Conclusions
(i) Prolactin is measured in at least 130 centres in the UK, mainly by kit methods. (ii) Many laboratories offering the assay analyse relatively few samples and depend on other centres and kit manufacturers for both reagents and reference data. The laboratories with the lowest workloads should be encouraged to send on their samples to larger local centres, and laboratories wishing to establish a prolactin service de novo should be asked to estimate the numbers involved and consider whether it is really necessary to take on the responsibility of the assay. (iii) Most kit users have an optimistic view of the true working range of their assay, taking the range of their standards to equal the working range. More guidance is needed both by kit manufacturers and by those involved in education on the means of making objective estimates of the capabilities of hormone immunoassays. Laboratories claiming wide working ranges rarely have QC pools at the high levels they claim to be measuring and consequently can have little idea of the variability of their assay at those levels.
BRIEF REVIEW OF AVAILABLE PROLACTIN
REAGENTS
Introduction
Prolactin immunoassays in current use do not differ in general from those for other polypeptide hormones. They involve the addition of tracer prolactin and anti-prolactin serum to suitably prepared calibration material or unknown specimens. After an incubation period of a few hours, antibody-free and bound fractions are separated and one, usually the bound fraction, counted. Commercial kits cost in the order of £1 per assay tube. Since it is recommended that all samples and standards are assayed in duplicate, the costs are in the order of £2·50 per patient specimen (including standards and QC samples) for reagents alone. The NHS reagents available from the Chelsea Hospital for Women and NETRIA cost about 10 pence per assay tube. Addresses are given in the appendix.
Standards
All prolactin assays, including kits, in the UK should be standardised against the current IRP 75/504. There is no doubt that a current cause of problems in the prolactin assay service in the UK is the limited availability of IRP 75/504, the lack of a suitable replacement and the inappropriate use of conversion factors, especially conversion from the mass units (e.g. ng/mL) commonly used in the USA (and thus popular with kit manufacturers) to international units (e.g. mUlL) and vice versa. The Chelsea kit uses amniotic fluid as a source of calibration material; it is calibrated directly against 75/504. A replacement for 75/504 is currently undergoing an international collaborative trial and should be available in 1986. This will allow appropriate calibration of kits, will allow the EQAS to conduct recovery experiments to establish the accuracy of the all laboratory trimmed mean (ALTM), and may reveal other causes of between-method bias concealed at present by confusion over standards.
The matrix diluent for the calibration material is important and a potential source of bias. Many commercial kits use human or animal serum. Others use a protein-buffer-saline diluent. Whatever the diluent (and no firm recommendation can be made), a thorough validation must be made, and bias effects (which occur predominantly at the separation ste,p) excluded.
Tracers
It is not recommended that individual centres undertake prolactin iodination for themselves as suitable well characterised 125I-prolactin is available from two NHS sources-NETRIA and Chelsea. Each preparation has a specific activity of approximately 50-100 f.lCi/f.lg and a shelf-life of up to 6 weeks. A number of laboratories have made direct comparisons between the two and they appear to be of similar high quality. Purified pituitary prolactin for iodination is available from Professor W R Butt, Birmingham for those. who wish to iodinate prolactin for their own in-house use. A number of different iodination procedures have been described. The clean-up procedure is important to ensure the removal of aggregated and dimerised material.
Antisera
Currently three antiserum preparations are available in the UK: (a) NETRIA anti-prolactin serum; (b) Birmingham anti-prolactin serum, code F 123/2; and (c) Guildhay anti-prolactin serum code G/R/51-VABC. The last is used in the Chelsea kit. These antiserum preparations seem to be of comparable avidity and specificity (cross-reaction from growth hormone being less than 1%) and comparisons of potency estimates of serum samples have shown goodagreernent, except on occasional samples at high levels. The latter may be due to different specificity toward the larger forms of prolactin and there is evidence that this is the case; as shown in Fig. 2 , the Guildhay antiserum responds somewhat less to 'big' prolactin than the other two.
Patient specimens
There are no special requirements for the handling and storage of specimens for prolactin assay; they are similar to gonadotrophins, for example. If specimens are to be diluted then the same diluent should be used as for the calibration material. Prolactin should be analysed in serum if possible, for plasma is more difficult to pipette with accuracy, and both the anticoagulant and the particulate material present can affect the separation system used in the assay, although the major methods used in the UK (NETRIA, Corning, Chelsea, Amersham) show no plasma/serum bias.
Separation systems
There appear to be no prolactin-specific factors or problems in the separation stage. Some problems experienced by Chelsea kit users in the UK EQAS have been ascribed to poolrelated phenomena associated with the QA specimens themselves and are not seen in internal QC or patient samples.
All assays for serum prolactin require a step to effect the separation of antibody-bound antigen from excess free antigen (RIA) or excess free antibody (immunometric assays). This step is potentially a source of both inaccuracy and imprecision. Inefficient separation of these fractions can lead to a rnisclassification of free into bound (or vice versa), with consequent effects on the non-specific binding. It can also lead to a situation where small differences in matrix between serum specimens, and particularly between standards and unknowns, result in different samples behaving in different ways in the same assay.
The most widely used separation technique for an RIA for serum prolactin is the conventional liquid double antibody technique, in which both non-immune carrier serum and second antibody are added and incubated under suitable conditions (e.g. at 4°C overnight). This technique is relatively slow but capable of producing low non-specific binding. No detailed recommendations can be used for in-house users since careful optimisation (e.g. of reagent concentrations and incubation times) is required with every batch of carrier serum or second antibody if matrix effects are to be minimised.
Currently, satisfactory approaches to speeding up the separation stage in prolactin immunoassay involve modification of this double antibody approach, e.g. PEG-assisted double antibody separation (NETRIA kit), solid-phase Assays for prolactin 647 linked antibody (Chelsea kit) and magnetisable solid-phase linked second antibody (Serono MAlA kit). Those undertaking their own modifications of the double antibody method will need to optimise them carefully to produce rugged systems with minimal bias. Immunometric assays generally involve solidphase technology for the separation step and assays so far developed have involved coupling of one antibody either to the plastic of the incubation tube or to a small particle of glass, cellulose, or sepharose. Thorough washing of the solid-phase linked antibody-antigenlabelled antibody complex is essential in order to reduce non-specific binding to low levels and so maximise precision over a wide working range. One advantage of immunometric assays in general, that of increased sensitivity, is not important in the case of prolactin since current assays are, quite correctly, targetted at a relatively high dose level.
REVIEW OF LABORATORY PERFORMANCE IN THE UK EQAS
The UK External Quality Assessment Scheme for serum prolactin provides an independent assessment of the performance of prolactin assays. Five serum samples are distributed monthly to participants, and the consensus mean, calculated from the logarithms of the result after 10% trimming of outliers, is taken as the target for each sample. Cumulative indices of performance (bias and variability) are calculated over a 6-month period. The main points emerging from the prolactin scheme when reviewed in December 1985 are as follows:
(i) The total number of participants has increased steadily since 1980 and is now 135. The major recent changes in methods used is a 4-5 fold increase in users of the Chelsea kit method. The most widely used methods (in decreasing order of use) are 'own' methods, NETRIA, Chelsea, Amersham and Corning. Labelled antibody methods are used by less than 10% of the participants but this is likely to increase. (ii) Performance has been assessed primarily using samples with prolactin concentrations in the normal range. Assays targetted at concentrations in the pathological ranges may not therefore be assessed in their optimal working range.
(iii) The lack of availability of a suitable primary calibrant (to replace IRP 751 504) has precluded the performance of recovery experiments to validate the accuracy of the all laboratory trimmed mean (ALTM), although the ALTM appears stable between distributions. (iv) Between-laboratory agreement among all participants is about 30% CV (geometric) for samples less than 250 mUlL, and 22% for samples greater than 250 mUlL. These figures indicate a relatively poor between-laboratory agreement.
(v) Comparisons between method groups
show that between-laboratory agreement is better within each group of kit users (Chelsea, NETRIA, Amersham) than within the own method users. The kit methods show similar betweenlaboratory agreement, although the Amersham shows a marked concentration dependence (Fig. 3 ). (vi) Median cumulative bias does not differ significantly between the own method, NETRIA, Corning and the Chelsea groups and is within 10% of the ALTM. (The bias shown by Chelsea kit users between October 1984 and March 1985 appears to have been related to particular EQAS pools distributed during that period which affected the Chelsea solid phase FSH and LH methods also.) The Amersham group of users has a marked bias of minus 25-40% which has remained relatively unchanged for several years (Fig. 4) . (vii) The median cumulative variability of the bias is 10-15% in the Amersham, Chelsea, NETRIA and Corning groups, and is significantly lower than in own method users. This suggests that these methods provide adequate within-laboratory precision. (viii) In conclusion, these data indicate that the NETRIA, Corning and Chelsea methods are most likely to provide the lowest bias (from the consensus value), together with the best betweenlaboratory agreement.
FURTHER RECOMMENDATIONS AND
FUTURE DEVELOPMENTS
Internal quality control
The fundamental approach to internal quality control of a serum prolactin assay is the same as for any other hormone, and readers are referred to other articles in this series. The ideal internal quality control programme should allow for assessment of within-batch precision for every assay performed, between-batch precision at several levels and accuracy as far as this can be assessed by recovery experiments. Systematic drift within prolactin assays can be checked by including a series of pools at the ., beginning and at the end of an assay batch. All laboratories performing prolactin assays should belong to the UK External Quality Assessment Scheme (UK EQAS), but they should rely on EQAS mainly for the assessment of bias; they should not regard it as a substitute for internal monitoring of between-batch precision.
The following recommendations are made for internal quality control of a serum prolactin assay:
(i) An accepted data processing program should be used, preferably one which constructs a within-batch precision profile for each assay from the replicates of standards, quality controls and unknown samples in addition to interpolating unknowns and QC pools. Programs suitable for microcomputers are now available from various sources. The intraassay coefficient of variation should be <10% over the range 100-1500 mUlL and should be below 5% around the upper limit of normality (700-1000 mUlL). (ii) Quality control pools based on human serum should be used which can be a selection of physiological, pathological and 'spiked' material, or mixtures of these. These pools may be prepared internally, but should be screened before use to ensure that they are negative for hepatitis B antigen. Screening of individual components for HTLV III virus is also recommended since the test is not reliable when applied to material pooled from several individuals. This virus is destroyed by heating at 56°C for 30 min but a possible effect of such treatment on prolactin estimates should be investigated before it is applied to QC material. (iii) Commercially available quality control serum may be used as an alternative to internally prepared material, but it is essential to ensure that the serum base is human in origin and that sensible target values have been used. A list of the commercial preparations is available from S.L.]. The cost is likely to be in the range £1-2 per mL. (iv) Large batches of either locally prepared or commercial quality control pools should be obtained for use over a 6--12 month period. These should be divided into aliquots suitable for each assay and stored either lyophilised or below -20°C. Simultaneous changes in batches of quality control pools and standards should be avoided. (v) A recognised system for charting all internal quality control information, including standard curve parameters, should be instituted. These charts should contain information relating to all changes in reagent batches. (vi) Inter-assay coefficients of variation for internal quality control pools in the range of 200-1500 mUlL should be less than 15% and preferably, less than 10%.
Criteria for rejection of samples or assays
The result for any individual sample should be rejected if the replication is less precise than an agreed level. For prolactin assays, a suggested figure for the upper limit of acceptable variation for differences between duplicate analyses is 15% of the mean. Rejected samples should be re-assayed, A result for an individual sample should also be rejected if it lies outside the working range of the standard curve. Low results could be reported as less than x mUlL (where x=assay sensitivity as determined by the precision profile), and high results could be reported at greater than y mUlL if appropriate, or diluted with a suitable diluent and reassayed. Criteria for deciding if a batch has passed QC scrutiny are dependent upon the application of good ground rules, tempered with common sense. In essence, the principle and practice are the same as those for other hormone analytes.
Alternative biological fluids for prolactin measurement
Prolactin is present in high concentrations in amniotic fluid but there is no clinical indication for its quantitative determination. Prolactin is metabolised by the liver and the kidneys, and excreted into urine but urinary prolactin estimation has not become established as a viable alternative to circulating levels. In general, as for other analytes, considerable care should be taken when attempting to measure prolactin in a medium other than serum, as the matrix will be different and this may result in changes in assay characteristics.
Possible new methodology
It can be anticipated that in the next few years there will be a move away from the current immunoassay methodology for serum prolactin towards the two-site immunometric assays. This move will be facilitated by the increasing availability of monoclonal antibodies against prolactin epitopes. As for other analytes, the immunometric assay offers several advantages over saturation analysis: greater sensitivity; potentially greater specificity; a wider working range for the standard curve; more rapid assays; and potentially greater precision.
However, there is evidence from other ana-Iytes (e.g. TSH) that the introduction of im-munometric assays based on different monoclonal antibodies may result in variable bias, and it will be particularly important for internal quality control and UK EQAS to address this problem.
In addition to a change in the basic principle of the assay, the next few years are likely to see a move away from the radioisotopic label, since the short shelf-life and relatively low specific radioactivity of these labels limit the potential usefulness of the immunometric assay. A variety of optical labels are under active evaluation at the present time and prolactin assays will probably appear based on cherniluminescene , enhanced luminescence, time-resolved fluorescence and enzyme amplification. Such assays will tend to be tied to standardised plastics (e.g. microtitre plates) and end-point detection apparatus and it is likely, therefore, that commercially developed assays will gain an increased share of the available market in the UK in the years to come.
